Citations

Clear

3942 citation(s) found for "To, Van".

Single Nucleotide Polymorphisms in the TP53 Region and Susceptibility to Invasive Epithelial Ovarian Cancer
Schildkraut, Joellen M. , Goode, Ellen L. , Clyde, Merlise A. , Iversen, Edwin S., Moorman, Patricia G. , Marks, Jeffrey R. , Lissowska, Jolanta , Brinton, Louise A. , Pepłońska, Beata , Cunningham, Julie M. , Vierkant, Robert A. , Rider, David N., Chenevix‐Trench, Georgia , Webb, Penelope M. , Beesley, Jonathan, Chen, Xiaoqing, Phelan, Catherine, Sutphen, Rebecca , Sellers, Thomas A. , Pearce, Leigh, Wu, Anna H. , Conti, David V. , Elund, Christopher K., Anderson, Rebecca L. , Goodman, Marc T. , Lurie, Galina, Carney, Michael E., Thompson, Pamela J., Gayther, Simon A. , Ramus, Susan J. , Jacobs, Ian , Kjær, Susanne K. , Høgdall, Estrid , Blaakær, Jan , Høgdall, Claus , Easton, Douglas F. , Song, Honglin , Whittemore, Alice S. , McGuire, Valerie , Quaye, Lydia, Terry, Kathryn L. , Hankinson, Susan E. , Tworoger, Shelley S. , García‐Closas, Montserrat , Cancer), Australian Cancer Study (Ovarian, Group, Australian Ovarian Cancer Study, Berchuck, Andrew , Chen, Xiaoqing, Berg, David Van Den , Pharoah, Paul D.P. , Anton‐Culver, Hoda , Ziogas, Argyrios , Cramer, Daniel W. , Calingaert, Brian , Chanock, Stephen Jacob , Sherman, Mark E. , Cancer), Australian Cancer Study (Ovarian, Group, Australian Ovarian Cancer Study, Kjaer, Susanne K , Ramus, Susan J , Tworoger, Shelley S , Webb, Penelope M , Vierkant, Robert A , Lissowska, Jolanta , García-Closas, Montserrat , Chenevix-Trench, Georgia , Høgdall, Estrid , Høgdall, Claus K , Conti, David V , Goodman, Marc T

Mayo Clinic

Cancer Research | March 10, 2009 | Volume: 69 | Issue: 6 | Pages: 2349-2357

10.1158/0008-5472.can-08-2902 | PMID 19276375 Get It

Abstract The p53 protein is critical for multiple cellular functions including cell growth and DNA repair. We assessed whether polymorphisms in the region encoding TP53 were associated with risk of invasive ovarian cancer. The study population includes a total of 5,206 invasive ovarian cancer cases (2,829 of which were serous) and 8,790 controls from 13 case-control or nested case-control studies participating in the Ovarian Cancer Association Consortium (OCAC). Three of the studies performed independent discovery investigations involving genotyping of up to 23 single nucleotide polymorphisms (SNP) in the TP53 region. Significant findings from this discovery phase were followed up for replication in the other OCAC studies. Mixed effects logistic regression was used to generate posterior median per allele odds ratios (OR), 95% probability intervals (PI), and Bayes factors (BF) for genotype associations. Five SNPs showed significant associations with risk in one or more of the discovery investigations and were followed up by OCAC. Mixed effects analysis confirmed associations with serous invasive cancers for two correlated (r2 = 0.62) SNPs: rs2287498 (median per allele OR, 1.30; 95% PI, 1.07–1.57) and rs12951053 (median per allele OR, 1.19; 95% PI, 1.01–1.38). Analyses of other histologic subtypes suggested similar associations with endometrioid but not with mucinous or clear cell cancers. This large study provides statistical evidence for a small increase in risk of ovarian cancer associated with common variants in the TP53 region. [Cancer Res 2009;69(6):2349–57]
Electrocorticography-guided resection of temporal cavernoma: is electrocorticography warranted and does it alter the surgical approach?
Rubio, Jesus, Cascino, Gregory D. , Meyer, Fredric B. , Gompel, Jamie J. Van , Worrell, Gregory A.

Mayo Clinic

Journal of Neurosurgery | February 13, 2009 | Volume: 110 | Issue: 6 | Pages: 1179-1185

10.3171/2008.10.jns08722 | PMID 19216651 Get It

Object Cavernous hemangiomas associated with epilepsy present an interesting surgical dilemma in terms of whether one should perform a pure lesionectomy or tailored resection, especially in the temporal lobe given the potential for cognitive damage. This decision is often guided by electrocorticography (ECoG), despite the lack of data regarding its value in cavernoma surgery. The purpose of the present study was several-fold: first, to determine the epilepsy outcome following resection of cavernomas in all brain regions; second, to evaluate the usefulness of ECoG in guiding surgical decision making; and third, to determine the optimum surgical approach for temporal lobe cavernomas. Methods The authors identified from their surgical database 173 patients who had undergone resection of cavernomas. One hundred two of these patients presented with epilepsy, and 61 harbored temporal lobe cavernomas. Preoperatively, all patients were initially evaluated by an epileptologist. The mean follow-up was 37 months. Results Regardless of the cavernoma location, surgery resulted in an excellent seizure control rate: Engel Class I outcome in 88% of patients at 2 years postoperatively. Of 61 patients with temporal lobe cavernomas, the mesial structures were involved in 35. Among the patients with temporal lobe cavernomas, those who underwent ECoG typically had a more extensive parenchymal resection rather than a lesionectomy (p < 0.0001). The use of ECoG in cases of temporal lobe cavernomas resulted in a superior seizure-free outcome: 79% (29 patients) versus 91% (23 patients) of patients at 6 months postresection, 77% (22 patients) versus 90% (20 patients) at 1 year, and 79% (14 patients) versus 83% (18 patients) at 2 years without ECoG versus with ECoG, respectively. Conclusions The surgical removal of cavernomas most often leads to an excellent epilepsy outcome. In cases of temporal lobe cavernomas, the more extensive the ECoG-guided resection, the better the seizure outcome. In addition to upholding the concept of kindling, the data in this study support the use of ECoG in temporal lobe cavernoma surgery in patients presenting with epilepsy.
CAD of colon cancer on CT colonography cases without cathartic bowel preparation
Linguraru, Marius George , Zhao, Shan , Uitert, Robert L. Van, Liu, Jiamin , Summers, Ronald M. , Fletcher, Joel G. , Manduca, Armando

Mayo Clinic

2008 30th Annual International Conference of the IEEE Engineering in Medicine and Biology Society | February 2, 2009 | Volume: No volume available | Issue: No issue available | Pages: 2996-2999

10.1109/iembs.2008.4649833 | PMID 19163336 Get It

Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease
Roher, Alex E., Esh, Chera L., Kokjohn, Tyler A., Castaño, Eduardo M., Vickle, Gregory D. Van, Kalback, Walter M., Patton, Rebekah , Luehrs, Dean C., Daugs, Ian D., Kuo, Yu‐Min , Emmerling, Mark R., Soares, Holly , Quinn, Joseph F. , Kaye, Jeffrey , Connor, Donald J., Silverberg, Nina, Seward, James D., Beach, Thomas G. , Adler, Charles H. , Sabbagh, Marwan Noel , Quinn, Joseph F

Mayo Clinic

Alzheimer's & Dementia | December 31, 2008 | Volume: 5 | Issue: 1 | Pages: 18-29

10.1016/j.jalz.2008.10.004 | PMID 19118806 Get It

BackgroundWe evaluated the amounts of amyloid beta (Aβ)) peptides in the central nervous system (CNS) and in reservoirs outside the CNS and their potential impact on Aβ plasma levels and Alzheimer's disease (AD) pathology.MethodsAmyloid β levels were measured in (1) the plasma of AD and nondemented (ND) controls in a longitudinal study, (2) the plasma of a cohort of AD patients receiving a cholinesterase inhibitor, and (3) the skeletal muscle, liver, aorta, platelets, leptomeningeal arteries, and in gray and white matter of AD and ND control subjects.ResultsPlasma Aβ levels fluctuated over time and among individuals, suggesting continuous contributions from brain and peripheral tissues and associations with reactive circulating proteins. Arteries with atherosclerosis had larger amounts of Aβ40 than disease‐free vessels. Inactivated platelets contained more Aβ peptides than activated ones. Substantially more Aβ was present in liver samples from ND patients. Overall, AD brain and skeletal muscle contained increased levels of Aβ.ConclusionsEfforts to use plasma levels of Aβ peptides as AD biomarkers or disease‐staging scales have failed. Peripheral tissues might contribute to both the circulating amyloid pool and AD pathology within the brain and its vasculature. The wide spread of plasma Aβ values is also due in part to the ability of Aβ to bind to a variety of plasma and membrane proteins. Sources outside the CNS must be accounted for because pharmacologic interventions to reduce cerebral amyloid are assessed by monitoring Aβ plasma levels. Furthermore, the long‐range impact of Aβ immunotherapy on peripheral Aβ sources should also be considered.
Bone Structure at the Distal Radius During Adolescent Growth
Kirmani, Salman , Christen, D. K. , Lenthe, Harry van , Bouxsein, Mary , McCready, Louise K., Melton, L. Joseph, Riggs, B. Lawrence, Amin, Shreyasee , Müller, Ralph , Khosla, Sundeep , Fischer, Philip R. , Khosla, Sundeep

Mayo Clinic

Journal of Bone and Mineral Research | December 29, 2008 | Volume: 24 | Issue: 6 | Pages: 1033-1042

10.1359/jbmr.081255 | PMID 19113916 Get It

Abstract The incidence of distal forearm fractures peaks during the adolescent growth spurt, but the structural basis for this is unclear. Thus, we studied healthy 6- to 21-yr-old girls (n = 66) and boys (n = 61) using high-resolution pQCT (voxel size, 82 μm) at the distal radius. Subjects were classified into five groups by bone-age: group I (prepuberty, 6–8 yr), group II (early puberty, 9–11 yr), group III (midpuberty, 12–14 yr), group IV (late puberty, 15–17 yr), and group V (postpuberty, 18–21 yr). Compared with group I, trabecular parameters (bone volume fraction, trabecular number, and thickness) did not change in girls but increased in boys from late puberty onward. Cortical thickness and density decreased from pre- to midpuberty in girls but were unchanged in boys, before rising to higher levels at the end of puberty in both sexes. Total bone strength, assessed using microfinite element models, increased linearly across bone age groups in both sexes, with boys showing greater bone strength than girls after midpuberty. The proportion of load borne by cortical bone, and the ratio of cortical to trabecular bone volume, decreased transiently during mid- to late puberty in both sexes, with apparent cortical porosity peaking during this time. This mirrors the incidence of distal forearm fractures in prior studies. We conclude that regional deficits in cortical bone may underlie the adolescent peak in forearm fractures. Whether these deficits are more severe in children who sustain forearm fractures or persist into later life warrants further study.
B7-H4–deficient mice display augmented neutrophil-mediated innate immunity
Zhu, Gefeng, Augustine, Mathew M., Azuma, Takeshi , Luo, Liqun , Yao, Sheng , Anand, Sudarshan , Rietz, A., Huang, Jiaqiang , Xu, Haiying, Flies, Andrew S. , Flies, Sarah J., Tamada, Koji , Colonna, Marco , Deursen, Jan M. A. van, Chen, Lieping , Colonna, Marco

Mayo Clinic

Blood | December 24, 2008 | Volume: 113 | Issue: 8 | Pages: 1759-1767

10.1182/blood-2008-01-133223 | PMID 19109567 Get It

Abstract B7-H4 is an immunoglobulin superfamily molecule and shown to be inhibitory for T-cell responses. To explore physiologic roles of B7-H4, we created B7-H4–deficient (KO) mice by genetic targeting. B7-H4KO mice are healthy and their T- and B-cell responses to polyclonal antigens are in normal range. However, B7-H4KO mice are more resistant to infection by Listeria monocytogenes than their littermates. Within 3 days after infection, bacterial colonies in livers and spleens are significantly lower than the controls, suggesting a role of B7-H4 in enhancing innate immunity. Further studies demonstrate that neutrophils increase in peripheral organs of B7-H4KO mice more so than their littermates but their bactericidal functions remain unchanged. Augmented innate resistance is completely dependent on neutrophils, even in the absence of adaptive immunity. In vitro B7-H4 inhibits the growth of bone marrow–derived neutrophil progenitors, suggesting an inhibitory function of B7-H4 in neutrophil expansion. Our results identify B7-H4 as a negative regulator of the neutrophil response to infection and provide a new target for manipulation of innate immunity.
Molecular Characterization of MSI-H Colorectal Cancer by MLHI Promoter Methylation, Immunohistochemistry, and Mismatch Repair Germline Mutation Screening
Poynter, Jenny N. , Weisenberger, Daniel J. , Long, Tiffany I. , Thibodeau, Stephen N. , Lindor, Noralane M. , Young, Joanne , Jenkins, Mark A. , Buchanan, Daniel D. , Levine, A. Joan, Gallinger, Steven, Bapat, Bharati , Potter, John D. , Haile, Robert W. , Investigators, for the Colon Cancer Family Registry, Siegmund, Kimberly D. , Hopper, John L. , Baron, John A. , Casey, Graham , Marchand, Loı̈c Le , Newcomb, Polly A. , Laird, Peter W. , Investigators, for the Colon Cancer Family Registry, Buchanan, Daniel D , Jenkins, Mark A , Haile, Robert W , Potter, John D

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | November 6, 2008 | Volume: 17 | Issue: 11 | Pages: 3208-3215

10.1158/1055-9965.epi-08-0512 | PMID 18990764 Get It

Abstract Microsatellite instability (MSI) occurs in 10% to 20% of colorectal cancers (CRC) and has been attributed to both MLH1 promoter hypermethylation and germline mutation in the mismatch repair (MMR) genes. We present results from a large population- and clinic-based study of MLH1 methylation, immunohistochemistry, and MMR germline mutations that enabled us to (a) estimate the prevalence of MMR germline mutations and MLH1 methylation among MSI-H cases and help us understand if all MSI-H CRC is explained by these mechanisms and (b) estimate the associations between MLH1 methylation and sex, age, and tumor location within the colon. MLH1 methylation was measured in 1,061 population-based and 172 clinic-based cases of CRC. Overall, we observed MLH1 methylation in 60% of population-based MSI-H cases and in 13% of clinic-based MSI-H cases. Within the population-based cases with MMR mutation screening and conclusive immunohistochemistry results, we identified a molecular event in MMR in 91% of MSI-H cases: 54% had MLH1 methylation, 14% had a germline mutation in a MMR gene, and 23% had immunohistochemistry evidence for loss of a MMR protein. We observed a striking age difference, with the prevalence of a MMR germline mutation more than 4-fold lower and the prevalence of MLH1 methylation more than 4-fold higher in cases diagnosed after the age of 50 years than in cases diagnosed before that age. We also determined that female sex is an independent predictor of MLH1 methylation within the MSI-H subgroup. These results reinforce the importance of distinguishing between the underlying causes of MSI in studies of etiology and prognosis. (Cancer Epidemiol Biomarkers Prev 2008;17(11):3208–15)
Risk Factors for Acute Graft-Versus-Host Disease After Human Leukocyte Antigen–Identical Sibling Transplants for Adults With Leukemia
Hahn, Theresa , Zhang, Mei-Jie , Wang, Dan , Arora, Mukta , Frangoul, Haydar , Hale, Gregory A., Horan, John , Isola, Luis , Rood, Jon J. van, Gupta, Vikas , Halter, Joerg , Reddy, Vijay , Tiberghien, Pierre , Litzow, Mark R. , Anasetti, Claudio , Pavletic, Stephen, Ringdén, Olle , Halter, Jörg , McCarthy, Philip L. , Gale, Robert Peter , Maziarz, Richard Thomas , Ringden, Olov , Gupta, Vikas

Mayo Clinic

Journal of Clinical Oncology | November 4, 2008 | Volume: 26 | Issue: 35 | Pages: 5728-5734

10.1200/jco.2008.17.6545 | PMID 18981462 Get It

Purpose Acute graft-versus-host disease (GVHD) causes substantial morbidity and mortality after human leukocyte antigen (HLA)-identical sibling transplants. No large registry studies of acute GVHD risk factors have been reported in two decades. Risk factors may have changed in this interval as transplant-related techniques have evolved. Patients and Methods Acute GVHD risk factors were analyzed in 1,960 adults after HLA-identical sibling myeloablative transplant for acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), or chronic myeloid leukemia (CML) reported by 226 centers worldwide to the Center for International Blood and Marrow Transplant Research from 1995 to 2002. Outcome was measured as time from transplant to onset of grade 2 to 4 acute GVHD, with death without acute GVHD as a competing risk. Results Cumulative incidence of grade 2 to 4 acute GVHD was 35% (95% CI, 33% to 37%). In multivariable analyses, factors significantly associated with grade 2 to 4 acute GVHD were cyclophosphamide + total-body irradiation versus busulfan + cyclophosphamide (relative risk [RR] = 1.4; P < .0001), blood cell versus bone marrow grafts in patients age 18 to 39 years (RR = 1.43; P = .0023), recipient age 40 and older versus age 18 to 39 years receiving bone marrow grafts (RR = 1.44; P = .0005), CML versus AML/ALL (RR = 1.35; P = .0003), white/Black versus Asian/Hispanic race (RR = 1.54; P = .0003), Karnofsky performance score less than 90 versus 90 to 100 (RR = 1.27; P = .014), and recipient/donor cytomegalovirus-seronegative versus either positive (RR = 1.20; P = .04). Stratification by disease showed the same significant predictors of grade 2 to 4 acute GVHD for CML; however, KPS and cytomegalovirus serostatus were not significant predictors for AML/ALL. Conclusion This analysis confirmed several previously reported risk factors for grade 2 to 4 acute GVHD. However, several new factors were identified whereas others are no longer significant. These new data may facilitate individualized risk estimates and raise several interesting biologic questions.
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping
Johnson, David C. , Corthals, Sophie L., Ramos, Christine, Hoering, Antje , Cocks, Kim , Dickens, Nicholas J. , Haessler, Jeff, Goldschmidt, H., Child, J. Anthony, Bell, Sue , Jackson, Graham , Baris, Dalsu , Rajkumar, S. Vincent , Davies, Faith E. , Durie, Brian G.M. , Crowley, John, Sonneveld, Pieter , Ness, Brian Van, Morgan, Gareth J. , Rajkumar, S Vincent , Davies, Faith E , Morgan, Gareth J

Mayo Clinic

Blood | September 20, 2008 | Volume: 112 | Issue: 13 | Pages: 4924-4934

10.1182/blood-2008-02-140434 | PMID 18805967 Get It

AbstractA venous thromboembolism (VTE) with the subsequent risk of pulmonary embolism is a major concern in the treatment of patients with multiple myeloma with thalidomide. The susceptibility to developing a VTE in response to thalidomide therapy is likely to be influenced by both genetic and environmental factors. To test genetic variation associated with treatment related VTE in patient peripheral blood DNA, we used a custom-built molecular inversion probe (MIP)–based single nucleotide polymorphism (SNP) chip containing 3404 SNPs. SNPs on the chip were selected in “functional regions” within 964 genes spanning 67 molecular pathways thought to be involved in the pathogenesis, treatment response, and side effects associated with myeloma therapy. Patients and controls were taken from 3 large clinical trials: Medical Research Council (MRC) Myeloma IX, Hovon-50, and Eastern Cooperative Oncology Group (ECOG) EA100, which compared conventional treatments with thalidomide in patients with myeloma. Our analysis showed that the set of SNPs associated with thalidomide-related VTE were enriched in genes and pathways important in drug transport/metabolism, DNA repair, and cytokine balance. The effects of the SNPs associated with thalidomide-related VTE may be functional at the level of the tumor cell, the tumor-related microenvironment, and the endothelium. The clinical trials described in this paper have been registered as follows: MRC Myeloma IX: ISRCTN68454111; Hovon-50: NCT00028886; and ECOG EA100: NCT00033332.
Insights into the dynamics of hereditary diffuse leukoencephalopathy with axonal spheroids
Gerpen, Jay A. van, Wider, Christian, Broderick, Daniel F. , Dickson, Dennis W. , Brown, Laura, Wszołek, Zbigniew K. , Dickson, Dennis W

Mayo Clinic

Neurology | September 15, 2008 | Volume: 71 | Issue: 12 | Pages: 925-929

10.1212/01.wnl.0000325916.30701.21 | PMID 18794495 Get It